Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK
13 août 2024 09h07 HE
|
Aclarion, Inc.
Vitality is a top 4 Provider of Private Medical Insurance in the UK.Aclarion now has Payer Coverage From 3 of the 4 Largest Private Health Insurers in the UK.Nearly 60% of all Patients With Private...
Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK
09 juil. 2024 07h00 HE
|
Aclarion, Inc.
Aviva is a Top 4 Provider of Private Medical Insurance in the UK By Joining AXA, Approximately 45% of Patients With Private Insurance Now Have Access to Nociscan in the Greater London Spine Care...
Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK
26 juin 2024 08h30 HE
|
Aclarion, Inc.
AXA is the 2nd Largest Provider of Private Medical Insurance in the UK Payer Coverage is the Most Important Catalyst Aclarion can Achieve to Drive Volume and Revenue AXA Represents the First...
Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London
25 juin 2024 08h30 HE
|
Aclarion, Inc.
Established in 1932, the London Clinic is the UK’s Most Renowned Independent, Private Hospital Payment to Aclarion for Each Nociscan is Being Increased From the Original Contract Contract...
Chronic Lower Back Pain Treatment Market Size to Surpass USD 4.52 Billion by 2030, exhibiting a CAGR of 9.5%
31 juil. 2023 05h25 HE
|
Fortune Business Insights
Pune, India, July 31, 2023 (GLOBE NEWSWIRE) -- The chronic lower back pain treatment market size was valued at USD 2.21 billion in 2022 and is projected to reach a valuation of USD 2.40 billion in...
Chronic Lower Back Pain Treatment Market Size [2022-2028] | Industry Share, Growth, Trends, Revenue, Competitive Landscape, Forecast Report
10 janv. 2022 04h51 HE
|
Fortune Business Insights
Pune, India, Jan. 10, 2022 (GLOBE NEWSWIRE) -- The rising prevalence of chronic pain across the world is expected to drive the global chronic lower back pain treatment market. As per the National...
Persica Pharmaceuticals has completed the first stage of its clinical trial on unique injectable PP353, to treat chronic lower back pain
19 août 2021 02h00 HE
|
Persica Pharmaceuticals
Persica Pharmaceuticals has completed the first stage of its clinical trial on unique injectable PP353, to treat chronic lower back pain Novel approach applicable to 20% of all CLBP populationsFirst...